Ertugliflozin in type 2 diabetes: a profile of its use
- 220 Downloads
Oral ertugliflozin (Steglatro™), a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, is approved in numerous countries as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes (T2D), either as monotherapy or add-on therapy to other antihyperglycaemic agents; specific indications may vary between individual countries. In numerous well-designed VERTIS trials and extension studies in adults with inadequately controlled T2D, ertugliflozin monotherapy, initial combination therapy to sitagliptin and add-on therapy to metformin or to metformin plus sitagliptin consistently provided effective and durable glycaemic control, and reduced bodyweight and blood pressure. Ertugliflozin is generally well tolerated, with a good benefit/risk profile. The availability of ertugliflozin/metformin (Segluromet™) and ertugliflozin/sitagliptin (Steglujan™) fixed-dose combinations (FDCs) may potentially improve compliance/adherence in patients requiring intensification of antihyperglycaemic treatment with combination therapy to achieve adequate glycaemic control. Given the proven benefits of other SGLT2 inhibitors on cardiovascular (CV) and renal outcomes, results from the ongoing VERTIS CV outcome trial are awaited with interest.
The manuscript was reviewed by: A. Antonelli, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; G. D. Dimitriadis, 2nd Department of Internal Medicine, Research Institute and Diabetes Center, Athens University Medical School, Attikon University Hospital, Athens, Greece. During the peer review process, Merck Sharp & Dohme B.V. and Pfizer Inc., the marketing-authorization holders of ertugliflozin, were offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Lesley Scott is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.
- 1.International Diabetes Federation. Diabetes: facts and figures. 2017. http://www.idf.org/. Accessed 6 May 2019.
- 11.Steglatro (ertugliflozin) 5 and 15 mg film-coated tablets: EU summary of product characteristics. Haarlem: Merck Sharp & Dohme B.V.; 2018.Google Scholar
- 12.Steglatro™ (ertugliflozin) tablet, film coated: US prescribing information. Whitehouse Station (NJ): Merck & Co Inc.; 2018.Google Scholar
- 13.Segluromet™ (ertugliflozin and metformin hydrochloride) tablet, film coated: US prescribing information. Whitehouse Station (NJ): Merck & Co Inc.; 2018.Google Scholar
- 14.Segluromet (ertugliflozin + metformin hydrochloride) 2.5 mg/850 mg, 2.5 mg/1,000 mg, 7.5 mg/850 mg and 7.5 mg/1,000 mg film-coated tablets: EU summary of product characteristics. Haarlem: Merck Sharp & Dohme B.V.; 2018.Google Scholar
- 15.Steglujan™ (ertugliflozin and sitagliptin) tablet, film coated: US prescribing information. Whitehouse Station (NJ): Merck & Co Inc.; 2018.Google Scholar
- 16.Steglujan (ertugliflozin + sitagliptin) 5 mg/100 mg and 15 mg/100 mg film-coated tablets: EU summary of product characteristics. Haarlem: Merck Sharp & Dohme B.V.; 2018.Google Scholar
- 17.Nucci G, Le V, Sweeney K, et al. Single- and multiple-dose pharmacokinetics and pharmacodynamics of ertugliflozin, an oral selective inhibitor of SGLT2, in healthy subjects [abstract no. PII-106]. Clin Pharmacol Ther. 2018;103(Suppl 1):S83.Google Scholar
- 20.Sahasrabudhe V, Saur D, Matschke K, et al. A phase 1, randomized, placebo- and active-controlled crossover study to determine the effect of single-dose ertugliflozin on QTc interval in healthy volunteers. Clin Pharmacol Drug Dev. 2018;20(5):512–23.Google Scholar
- 32.Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019. https://doi.org/10.1111/dom.13631.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Hollander P, Hill J, Johnson J, et al. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019. https://doi.org/10.1080/03007995.2019.1583450.CrossRefPubMedGoogle Scholar
- 37.Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–40.CrossRefGoogle Scholar
- 44.Patel SM, Hickman MA, Frederich R, et al. Evaluation of osmotic diuresis and volume depletion events in patients with type 2 diabetes mellitus (T2DM) receiving ertugliflozin [abstract no. 1169-P]. Diabetes. 2018;67(Suppl 1):A313.Google Scholar
- 45.Patel SM, Hickman MA, Frederich R, et al. Assessment of adverse renal effects in patients with type 2 diabetes mellitus (T2DM) receiving ertugliflozin [abstract no. 1168-P]. Diabetes. 2018;67(Suppl. 1):A313.Google Scholar
- 46.Hickman MA, Patel S, Lauring B, et al. Incidence of urinary tract infections in patients with type 2 diabetes receiving ertugliflozin, placebo or active comparator [abstract no. 630]. Diabetologia. 2018;61(Suppl 1):S306.Google Scholar
- 47.Hickman MA, Frederich R, Patel SM, et al. Evaluation of fractures, bone mineral density (BMD), and bone biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving ertugliflozin [abstract no. 1145-P]. Diabetes. 2018;67(Suppl 1):A307.Google Scholar
- 48.National Institute for Health and Care Excellence. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. 2019. http://www.nice.org.uk/guidance/ta572. Accessed 5 May 2019.